SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MYL -Mylan
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Judy who wrote (5)11/16/1999 10:04:00 PM
From: Spekulatius  Read Replies (1) of 9
 
I would not bet on MYL beating earning estimates. Revenues have only been growing at a 5% rate for the last two quarters, but costs have been up more, squeezing earnings.
Mylan has a very sound balance sheet and will recover.
However,its management does not appear to be shareholder friendly and stock dilution is significant.
After studying the generics companies,I believe Watson (WPI) may have a better management and its stock may be the better investment.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News